Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2, multi center, randomized, double-blind, placebo controlled, dose escalation study to evaluate the safety, tolerability, PK, and activity of ISIS 113715 administered weekly in subjects with type 2 DM [diabetes mellitus] treated w/ sulfonurea.

Next Previous
X
Search
Trial Profile

A phase 2, multi center, randomized, double-blind, placebo controlled, dose escalation study to evaluate the safety, tolerability, PK, and activity of ISIS 113715 administered weekly in subjects with type 2 DM [diabetes mellitus] treated w/ sulfonurea.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ISIS 113715 (Primary) ; Sulfonylureas
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use

    • Most Recent Events

    • 02 Jul 2010 Results presented at the 70th Annual Scientific Sessions of the American Diabetes Association
    • 29 Jun 2010 Results presented at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA-2010), according to a Isis Pharmaceuticals media release.
    • 21 Oct 2009 Top-line results have been reported by Isis in a media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top